

# HFSA 2026 Preview – Clinical and AI / ML



**LucidQuest Intelligence**  
Accelerate your success



# HFSA 2026 Preview – Table of Contents

|                                                                                     |                              |
|-------------------------------------------------------------------------------------|------------------------------|
| • <a href="#"><u>New Trends in Heart Failure Treatment Strategy At HFSA'26</u></a>  | <a href="#"><u>3-5</u></a>   |
| • <a href="#"><u>Key Sessions To Watch</u></a>                                      | <a href="#"><u>6-7</u></a>   |
| • <a href="#"><u>Industry-sponsored Sessions &amp; Focus Areas At HFSA 2026</u></a> | <a href="#"><u>8-16</u></a>  |
| • <a href="#"><u>Competitive Landscape At a Glance at HFSA 2026</u></a>             | <a href="#"><u>9-10</u></a>  |
| • <a href="#"><u>Key Industry-sponsored Sessions At HFSA 2026</u></a>               | <a href="#"><u>11-15</u></a> |
| • <a href="#"><u>Emerging Assets &amp; Approaches at HFSA 2026</u></a>              | <a href="#"><u>16</u></a>    |
| • <a href="#"><u>AI/ML Trends &amp; Strategic Watchpoints At HFSA 2026</u></a>      | <a href="#"><u>17-19</u></a> |
| • <a href="#"><u>AI / Digital Health Angle At HFSA 2026</u></a>                     | <a href="#"><u>18-19</u></a> |
| • <a href="#"><u>What We're Watching For Post-congress</u></a>                      | <a href="#"><u>20</u></a>    |
| • <a href="#"><u>Get In Touch With LucidQuest</u></a>                               | <a href="#"><u>21</u></a>    |



- **HFpEF treatment is set to expand beyond conventional pharmacological management**

- HFSA 2026 is expected to bring together approaches spanning nonsteroidal MRAs, SGLT2 inhibition, metabolic interventions, anti-obesity therapies and device-based strategies in HFpEF. Sessions will examine whether targeting congestion, metabolism, obesity and underlying hemodynamic abnormalities can broaden treatment options beyond established approaches



- **ATTR-CM is moving toward earlier identification and more targeted disease management**

- The programme will place increasing emphasis on ATTR-CM screening in HFpEF clinics, multimodality diagnosis, TTR stabilization and disease-modifying therapies. Discussions around acoramidis, eplontersen and amyloid imaging are expected to examine how earlier recognition and targeted intervention could reshape the ATTR-CM treatment pathway





- **Cardiac myosin inhibition is set to expand across the HCM treatment landscape**

- HFSA 2026 will feature substantial attention on aficamten, including ACACIA-HCM results in nonobstructive HCM and analyses of exercise performance. The programme will help assess whether cardiac myosin inhibition can extend beyond obstructive disease and provide meaningful improvements across broader HCM populations



- **Cardiogenic shock management is set to focus increasingly on treatment intensity and patient selection**

- Dedicated sessions will examine temporary mechanical circulatory support, percutaneous LVAD use, device selection, unloading strategies and the definition of treatment success in HF-related cardiogenic shock. The discussion is expected to highlight the balance between early aggressive intervention and tailoring mechanical support to individual patient profiles



- **Precision medicine and genetic therapies are moving closer to the heart-failure treatment paradigm**

- HFSA 2026 will feature genetic testing implementation, precision omics, gene-targeted therapies and clinical trials in cardiomyopathy, alongside emerging approaches such as AFTX-201 for BAG3-associated DCM. These sessions are expected to examine how molecular characterization could increasingly influence diagnosis, patient selection and treatment development



- **Heart-failure care is set to become more connected through devices, remote monitoring and AI**

- The programme will explore remote hemodynamic monitoring, sustainable remote HF clinics, AI-enabled decision support and emerging device-based therapies, including cardiac contractility modulation and other approaches for HFpEF. The key focus will be whether connected technologies can support earlier identification of deterioration and more proactive, personalised HF management



# Key Sessions To Watch (1/2)

| Date        | Session Title (short)                                                | Type                | Author / Institution                                    | Why Watch                                                                                                                                               |
|-------------|----------------------------------------------------------------------|---------------------|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09 Oct 2026 | The Future of AI-Enabled Heart Failure Care: ARPA-H ADVOCATE Program | Pre-Meeting Event   | Haider Warraich / Boston Medical Center                 | Expected to explore how AI-enabled approaches could support future HF care, decision-making and clinical workflows                                      |
| 09 Oct 2026 | Up for Debate: Shock and Advanced HF – When to Trigger Pumps?        | Pre-Meeting Event   | Jennifer Cowger / Henry Ford Health                     | Set to examine the timing of mechanical circulatory support and the balance between earlier intervention and patient selection in advanced HF and shock |
| 09 Oct 2026 | Trial Tinder: Emerging Device-Based HF Trials                        | Pre-Meeting Event   | Multiple investigators                                  | Will spotlight emerging approaches including Reprieve, DORAYA-HF, Aortix, NORM-HF, VOICE-HF, ALLAY-HF, BENEFIT-HF and C-MIC IV                          |
| 10 Oct 2026 | ATTR-CM Screening in HFpEF Clinics: PRO vs CON                       | Scientific Sessions | Kavita Sharma / Johns Hopkins                           | Expected to test whether near-universal ATTR-CM screening should become part of the HFpEF diagnostic pathway                                            |
| 10 Oct 2026 | Which MRA Crosses the Finish Line First?                             | Scientific Sessions | Andrew Sauer / Saint Luke's Mid America Heart Institute | Set to compare MRA and nonsteroidal MRA approaches in HFpEF and highlight the evolving pharmacological treatment landscape                              |
| 10 Oct 2026 | AFTX-201 in BAG3-Associated Dilated Cardiomyopathy                   | Oral                | Charles Albright / Affinia Therapeutics                 | Expected to provide early clinical evidence for a genetically targeted approach in BAG3-associated DCM                                                  |
| 11 Oct 2026 | Tovinontrine: Phase 2 Results in Chronic HF                          | Plenary Session     | James Udelson / Tufts Medical Center                    | Key readout across both HFrEF and HFpEF that could clarify the potential role of tovinontrine as an additional treatment approach                       |



# Key Sessions To Watch (2/2)

| Date        | Session Title (short)                                         | Type               | Author / Institution                             | Why Watch                                                                                                                               |
|-------------|---------------------------------------------------------------|--------------------|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| 11 Oct 2026 | Eplontersen: CARDIO-TTTransform Health Status Data            | Plenary Session    | James Udelson / Tufts Medical Center             | Key readout across both HFrEF and HFpEF that could clarify the potential role of tovinontrine as an additional treatment approach       |
| 11 Oct 2026 | 124I-Evuzamitide PET/CT in Cardiac Amyloidosis                | Plenary Session    | Mathew Maurer / Columbia University              | Expected to assess a non-invasive imaging approach for earlier detection of cardiac amyloidosis and its potential clinical utility      |
| 11 Oct 2026 | Aficamten: ACACIA-HCM in Nonobstructive HCM                   | Scientific Session | Ahmad Masri / Oregon Health & Science University | Expected to provide further evidence on aficamten in symptomatic nonobstructive HCM and broaden the cardiac myosin inhibition landscape |
| 12 Oct 2026 | Aficamten: Global Efficacy in Nonobstructive HCM – ACACIA-HCM | Plenary Session    | Martin Maron / Lahey Hospital & Medical Center   | Major efficacy readout that could clarify the potential role of aficamten across the nonobstructive HCM population                      |
| 12 Oct 2026 | Aficamten: Exercise Performance in Nonobstructive HCM         | Plenary Session    | Gregory Lewis / Massachusetts General Hospital   | Expected to provide additional evidence on functional and exercise-related benefits of cardiac myosin inhibition                        |

# Industry-Sponsored Sessions & Focus Areas – HFSA 2026





# HFSA 2026– Competitive Landscape at a Glance (1/2)

| Name                                                | Sessions | Companies / Assets                                                     | Why It Matters                                                                                                                                                                                    |
|-----------------------------------------------------|----------|------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ATTR-CM treatment & diagnosis                       | Multiple | Alnylam / vutrisiran; Pfizer; BridgeBio; eplontersen; 124I-evuzamitide | HFSA 2026 will highlight increasing competition around TTR stabilization and RNA-targeted approaches, with earlier diagnosis and disease modification becoming important areas of differentiation |
| Nonobstructive HCM & cardiac myosin inhibition      | Multiple | Cytokinetics / aficamten; BMS / mavacamten                             | The congress will provide an important view of whether cardiac myosin inhibition can expand treatment options in nonobstructive HCM and differentiate through functional and exercise outcomes    |
| Genetic & gene-targeted therapies in cardiomyopathy | Multiple | Affinia Therapeutics / AFTX-201                                        | HFSA 2026 is set to highlight a shift toward genetically defined HF populations, with emerging therapies potentially moving treatment beyond conventional pharmacological approaches              |
| Device-based HF therapy                             | Multiple | CVRx / Barostim; Abbott; Edwards Lifesciences                          | The focus will increasingly extend beyond pharmacological therapy toward devices targeting haemodynamics, neurohormonal pathways and cardiac function across different HF populations             |



# HFSA 2026– Competitive Landscape at a Glance (2/2)

| Name                                               | Sessions | Companies / Assets                                             | Why It Matters                                                                                                                                                            |
|----------------------------------------------------|----------|----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Remote monitoring & connected HF care              | Multiple | CVRx; Abbott; Analog Devices / Sensinel                        | HFSA 2026 will explore whether remote haemodynamic and sensor-based monitoring can enable earlier intervention and reduce worsening HF and hospitalisation                |
| AI-enabled HF management                           | Multiple | ARPA-H ADVOCATE; AI-enabled clinical decision support          | The programme will examine whether AI can move beyond research applications toward clinical decision support, medication optimisation and more proactive HF management    |
| Cardiogenic shock & mechanical circulatory support | Multiple | Temporary MCS; percutaneous LVADs                              | Competition will increasingly centre on patient selection, timing of intervention and the optimal use of mechanical circulatory support in cardiogenic shock              |
| HFpEF: pharmacological & device innovation         | Multiple | SGLT2 inhibitors; MRAs/nonsteroidal MRAs; metabolic approaches | The HFpEF landscape is set to broaden beyond established therapies, with competition increasingly focused on congestion, metabolic drivers and haemodynamic abnormalities |



# Key Industry-Sponsored Sessions at HFSA 2026 (1/5)



- **Boehringer Ingelheim:**

- Focus Areas: RAAS Dysregulation, Aldosterone & HF
- Boehringer Ingelheim's programme is expected to examine RAAS dysregulation and the role of aldosterone in HF, bringing greater attention to underlying biological drivers of disease and their implications for treatment strategy



- **Pfizer:**

- Focus Areas: ATTR-CM, Diagnosis, Treatment & Monitoring
- Pfizer is set to address the evolving ATTR-CM treatment pathway, spanning contemporary approaches to diagnosis, treatment and monitoring. The session is expected to highlight how improved recognition and disease management could shape clinical decision-making as the ATTR-CM landscape evolves



# Key Industry-Sponsored Sessions at HFSA 2026 (2/5)



- **Bristol Myers Squibb:**

- Focus Areas: Obstructive HCM & Evidence-to-Practice Translation
- BMS is set to explore obstructive HCM and the translation of clinical evidence into practice, highlighting how established and emerging HCM treatment strategies can be integrated into routine care



- **Alnylam:**

- Focus Areas: ATTR-CM, Vutrisiran & Clinical Decision-Making
- Alnylam is set to feature ATTR-CM and vutrisiran, including an industry innovation event focused on translating the evolving evidence base into confident clinical decisions. A separate session will introduce AMVUTTRA® (vutrisiran), reinforcing the company's focus on RNAi-based disease modification in ATTR-CM



# Key Industry-Sponsored Sessions at HFSA 2026 (3/5)



- **Abbott:**

- Focus Areas: HF Innovation, Devices & Emerging Care Models
- Abbott's programme is set to bring together ideas and innovations transforming HF care, contributing to the broader device and technology discussion at HFSA. The focus is expected to reflect the expanding role of technology alongside conventional HF treatment



- **Affinia Therapeutics:**

- Focus Areas: BAG3-Associated DCM & AFTX-201 Gene Therapy
- Affinia Therapeutics is set to highlight AFTX-201, an investigational gene therapy for BAG3-associated DCM, through the UPBEAT trial. The programme adds a genetically targeted approach to the HF landscape and could provide an important look at the movement toward precision treatment in cardiomyopathy



# Key Industry-Sponsored Sessions at HFSA 2026 (4/5)



## • **BridgeBio:**

- Focus Areas: ATTR-CM, TTR Stabilization & Treatment
- BridgeBio is set to examine ATTR-CM diagnosis and treatment with a TTR stabilizer, contributing to the increasingly competitive disease-modifying treatment landscape. The focus is expected to centre on translating an evolving evidence base into practical clinical decision-making



## • **ZOLL:**

- Focus Areas: Sudden Cardiac Death Risk & HF
- ZOLL's programme is expected to address early SCD risk in HF, bringing greater attention to risk identification and intervention before adverse events occur. The discussion could strengthen the role of proactive risk assessment within broader HF management strategies



# Key Industry-Sponsored Sessions at HFSA 2026 (5/5)



## • **Cytokinetics:**

- Focus Areas: Cardiac Myosin Inhibition, HCM & AI in HF
- Cytokinetics is set to feature both cardiac myosin inhibition in obstructive HCM and the use of AI in HF, linking therapeutic innovation with emerging digital approaches. The programme is expected to highlight how new treatment modalities and data-driven care could reshape cardiovascular management



## • **Edwards Lifesciences:**

- Focus Areas: Future of Heart Failure Care & Device Innovation
- Edwards Lifesciences is set to focus on the future of HF care, reinforcing the growing role of device-based approaches within the evolving treatment landscape. The programme is expected to contribute to broader discussions around how innovation could complement pharmacological management





# Emerging Assets & Approaches at HFSA 2026

| Asset / Approach                    | 2026 Presence                                                                    |
|-------------------------------------|----------------------------------------------------------------------------------|
| <b>Tovinontrine</b>                 | Phase 2 randomized study in chronic heart failure                                |
| <b>Aficamten</b>                    | ACACIA-HCM results in nonobstructive HCM; SEQUOIA-HCM analysis                   |
| <b>Eplontersen</b>                  | CARDIO-TTRansform health-status data in ATTR-CM                                  |
| <b>124I-Evuzamitide</b>             | Phase 3 prospective cardiac amyloidosis PET/CT cohort                            |
| <b>AFTX-201</b>                     | Investigational AAV gene therapy in BAG3-associated dilated cardiomyopathy (DCM) |
| <b>STM-01</b>                       | First-in-human Phase 1 cardiac progenitor cell therapy in HFpEF                  |
| <b>INSPIRE System</b>               | Safety, efficacy and cardiovascular outcomes in HF                               |
| <b>Cardiac microcurrent therapy</b> | C-MIC II and C-MIC III outcomes                                                  |



# AI/ML Trends & Strategic Watchpoints at HFSA 2026





# AI / Digital Health Angle at HFSA 2026 (1/2)

- **AI and digital-health presentations at HFSA 2026 will largely focus on clinical decision support, cardiac amyloidosis assessment, treatment optimisation and remote monitoring, rather than AI-enabled drug discovery or broad technology adoption. Sessions on AI-enabled heart-failure care, AI-supported mapping of organ involvement, electronic interventions for guideline-directed therapy and remote monitoring will examine how these tools could support clinical assessment, treatment decisions and longitudinal HF management**
- **The most relevant signal will be whether AI and digital approaches can move beyond emerging applications toward clinically actionable tools that complement physician decision-making. This will be particularly important in heart-failure treatment optimisation, cardiac amyloidosis assessment and monitoring of worsening HF, where HFSA 2026 is expected to explore how technology can translate complex patient-level data into earlier and more informed intervention**
- **Key sessions include:**
  - The Future of AI-Enabled Heart Failure Care: The ARPA-H ADVOCATE Program
  - The Wizard's Algorithm: Integrating AI to Map Organ Involvement
  - TAILORD: An Electronic Intervention to Improve Guideline-Directed Medical Therapy



# AI / Digital Health Angle at HFSA 2026 (2/2)

- Is Remote Monitoring the Answer to Outpatient Management of Worsening HF?
- AI and precision-omics approaches in heart failure
- Remote monitoring and sensor-based approaches for longitudinal HF management
- Digital approaches to medication optimisation and outpatient care
- **Sessions suggest AI and digital tools are increasingly being used to improve:**
  - Clinical decision support and integration of AI into HF care workflows
  - Treatment optimisation and implementation of guideline-directed medical therapy
  - Multisystem assessment and organ involvement mapping in cardiac amyloidosis
  - Remote monitoring and earlier identification of worsening HF
  - Risk assessment and precision HF care through multimarker, proteomic and patient-level data
  - Outpatient and longitudinal HF management through connected digital approaches



# What We're Watching for Post-HFSA 2026

- Whether **Tovinontrine** generates sufficient efficacy and safety evidence to support further development as a differentiated heart-failure therapy
- Whether **aficamten** strengthens the role of cardiac myosin inhibition across both obstructive and nonobstructive HCM
- Whether **emerging ATTR-CM data** further shift the field toward earlier diagnosis, disease modification and longitudinal monitoring
- Whether **gene- and cell-based approaches**, including AFTX-201 and STM-01, provide enough clinical evidence to support broader development in cardiomyopathy and HFpEF
- Whether **device-based approaches** such as Barostim, cardiac contractility modulation and cardiac microcurrent therapy demonstrate sufficient real-world or clinical benefit to expand their role in HF management
- Whether **AI and remote-monitoring approaches** move beyond proof-of-concept toward routine, clinically actionable HF decision support
- Whether **cardiometabolic approaches**, including GLP-1 therapies and weight-loss strategies, become increasingly integrated into HFpEF management
- Whether **implementation-focused approaches** to outpatient care, genetic testing and remote monitoring translate innovation into more accessible and effective HF care



# Strategic Insights and Strategy Development is our focus

COMPETITIVE STRATEGY  
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL  
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS  
DISEASES



INVESTMENT INSIGHTS

e: [INFO@LQVENTURES.COM](mailto:INFO@LQVENTURES.COM)

w: [WWW.LQVENTURES.COM](http://WWW.LQVENTURES.COM)